BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28011985)

  • 21. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
    Rossi HA; Becker PS; Emmons RV; Westervelt P; Levy W; Liu Q; Clark Y; Ballen K
    Bone Marrow Transplant; 2003 Mar; 31(6):441-6. PubMed ID: 12665838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom's Macroglobulinemia.
    Heini AD; Beck P; Bacher U; Seipel K; Zander T; Daskalakis M; Pabst T
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
    Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
    Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
    Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C
    Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.
    Robinson SP; Boumendil A; Finel H; Dreger P; Sureda A; Hermine O; Montoto S
    Bone Marrow Transplant; 2018 Dec; 53(12):1553-1559. PubMed ID: 29884850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL-A Pilot Study.
    Stoffel T; Bacher U; Banz Y; Daskalakis M; Novak U; Pabst T
    J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35807041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
    Musso M; Scalone R; Marcacci G; Lanza F; Di Renzo N; Cascavilla N; Di Bartolomeo P; Crescimanno A; Perrone T; Pinto A
    Bone Marrow Transplant; 2010 Jul; 45(7):1147-53. PubMed ID: 19898504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the Efficacy of Modified BeEAM(Bendamustine, Etoposide, Cytarabine, Melphalan) Regimen as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma: An Experience from Two Centers of a Developing Country.
    Ramzi M; Vafaie E; Haghighinejad H; Imran H
    Int J Hematol Oncol Stem Cell Res; 2023 Apr; 17(2):106-113. PubMed ID: 37637764
    [No Abstract]   [Full Text] [Related]  

  • 31. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Sivaraj D; Bacon W; Long GD; Rizzieri DA; Horwitz ME; Sullivan KM; Kang Y; Li Z; Chao NJ; Gasparetto C
    Bone Marrow Transplant; 2018 Jan; 53(1):34-38. PubMed ID: 29084203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity.
    Yeral M; Aytan P; Gungor B; Boga C; Unal A; Koc Y; Kaynar L; Buyukkurt N; Eser B; Ozdoğu H
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):652-660. PubMed ID: 32605899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
    Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
    Kothari J; Foley M; Peggs KS; Mackenzie S; Thomson K; Morris E; Ardeshna KM; Virchis AE; Linch DC; Lambert J
    Bone Marrow Transplant; 2016 Oct; 51(10):1397-1399. PubMed ID: 27214072
    [No Abstract]   [Full Text] [Related]  

  • 35. Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma.
    Tardy MP; Gastaud L; Ojeda-Uribe M; Boscagli A; Caruso S; Skaf R; Gutnecht J; Thyss A; Peyrade F
    Exp Hematol Oncol; 2015; 4():18. PubMed ID: 26185733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
    Sugimoto M; Ito S; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Ashizawa M; Yamamoto C; Fujiwara S; Okazuka K; Hatano K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kako S; Kanda Y
    Ann Hematol; 2016 Sep; 95(9):1513-9. PubMed ID: 27365141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
    Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
    Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
    Cao TM; Negrin RS; Stockerl-Goldstein KE; Johnston LJ; Shizuru JA; Taylor TL; Rizk NW; Wong RM; Blume KG; Hu WW
    Biol Blood Marrow Transplant; 2000; 6(4):387-94. PubMed ID: 10917574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.